Addex raises USD 2.8 million via ATM offering
Analysis based on 6 articles · First reported Aug 26, 2026 · Last updated Aug 26, 2026
The capital raise provides Addex with additional funding to support its clinical programs, extending its cash runway into late 2027. This modest offering may slightly dilute existing shareholders but signals continued financial support from investors, potentially stabilizing the stock.
Addex Therapeutics, a clinical-stage biopharmaceutical company, announced on August 26, 2026, that it raised gross proceeds of USD 2.8 million (CHF 2.2 million) through the sale of 437,869 American Depositary Shares (ADSs) representing 52,544,280 shares, under its At the Market (ATM) offering agreement with H.C. Wainwright & Co. The proceeds extend the company's cash runway to the fourth quarter of 2027. Following the sale, outstanding shares increased to 210,292,217, while issued shares remained at 218,654,496. Addex continues to develop allosteric modulators for neurological disorders, with lead candidate dipraglurant and partnerships including Indivior.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard